background
gener
popul
larg
naiv
infl
uenza
antibodi
gener
allow
analysi
novel
infl
uenza
vaccin
independ
background
immun
previou
infect
assess
safeti
immunogen
dna
encod
prime
vaccin
improv
antibodi
respons
inactiv
infl
uenza
vaccin
vrc
vrc
two
sequenti
enrol
phase
openlabel
randomis
clinic
trial
healthi
adult
age
year
randomli
assign
receiv
intramuscular
dna
mg
day
twice
day
week
follow
monoval
inactiv
vaccin
miv
week
compar
twodos
regimen
miv
either
week
interv
antibodi
respons
assess
haemagglutin
inhibit
hai
elisa
neutralis
id
immunoassay
stemdirect
antibodi
cell
respons
assess
intracellular
cytokin
stain
enrol
investig
individu
mask
group
assign
vrc
vrc
regist
clinicaltrialsgov
number
respect
vrc
individu
randomli
assign
four
group
receiv
vaccin
vrc
individu
enrol
receiv
vaccin
nine
receiv
twodos
regimen
miv
receiv
dna
day
follow
miv
week
dna
prime
safe
enhanc
c
antibodi
titr
follow
miv
boost
especi
interv
dna
prime
miv
boost
extend
week
two
studi
dna
prime
miv
boost
interv
induc
protect
hai
titr
individu
increas
geometr
mean
titr
gmt
four
time
individu
given
mivmiv
regimen
week
gmt
vs
gmt
addit
neutralis
antibodi
direct
conserv
stem
region
induc
primeboost
regimen
sever
individu
vaccinerel
seriou
advers
event
record
interpret
dna
prime
week
advanc
infl
uenza
vaccin
boost
increas
magnitud
protect
antibodi
respons
hai
case
induc
haemagglutininstemspecifi
c
neutralis
antibodi
dnamiv
vaccin
regimen
could
enhanc
effi
caci
infl
uenza
vaccin
show
antistem
antibodi
elicit
vaccin
man
worldwid
burden
infl
uenza
remain
substanti
estim
peopl
die
infl
uenza
everi
year
substanti
public
health
eff
ect
infl
uenza
infect
compound
potenti
pandem
caus
emerg
viru
strain
immun
exist
popul
episod
occur
infl
uenza
subtyp
fi
rst
identifi
ed
human
be
caus
spanish
fl
u
pandem
mortal
estim
million
death
worldwid
relat
viru
caus
pandem
deriv
tripl
reassort
gene
swine
avian
human
infl
uenza
virus
type
adapt
anim
infl
uenza
virus
man
repres
global
threat
public
health
anoth
exampl
zoonot
spread
includ
highli
pathogen
avian
infl
uenza
virus
caus
morbid
mortal
bird
popul
caus
sporad
human
diseas
june
report
confi
rmed
human
case
death
addit
repres
highli
pathogen
strain
absenc
background
immun
gener
popul
make
antigen
ideal
assess
novel
infl
uenza
vaccin
approach
protect
infl
uenza
mainli
antibodymedi
respons
infl
uenza
vaccin
typic
measur
haemagglutin
inhibit
assay
hai
antibodi
direct
well
defi
ned
antigen
site
globular
head
region
infl
uenza
haemagglutinin
larg
strainspecifi
c
hai
titr
typic
associ
least
reduct
risk
infect
strain
specifi
c
infl
uenza
virus
human
be
contrast
neutralis
antibodi
assay
detect
function
antibodi
capac
inhibit
viral
entri
cell
case
infl
uenza
neutralis
antibodi
specifi
c
head
haemagglutinin
direct
conserv
region
stem
haemagglutinin
abl
neutralis
multipl
subtyp
infl
uenza
specifi
calli
localis
region
haemagglutinin
stem
identifi
ed
import
antigen
site
capabl
induc
broadli
neutralis
antibodi
region
highli
conserv
among
group
infl
uenza
type
virus
although
neutralis
stemspecifi
c
haemagglutinin
antibodi
identifi
ed
man
stem
antibodi
respons
elicit
vaccin
vaccin
regimen
could
induc
antibodi
conserv
antigen
target
would
repres
import
step
toward
univers
infl
uenza
vaccin
develop
genebas
vaccin
shown
induc
crossneutralis
antibodi
direct
conserv
region
haemagglutinin
stem
protect
infect
multipl
strain
infl
uenza
anim
assess
similar
vaccin
regimen
man
investig
abil
elicit
hai
neutralis
antibodi
respons
includ
direct
highli
conserv
stem
region
background
respons
due
previou
infect
virus
address
question
dna
vaccin
encod
prime
vaccin
prime
follow
monoval
inactiv
vaccin
miv
boost
phase
safeti
immunogen
studi
test
abil
primeboost
regimen
induc
improv
antibodi
respons
autolog
viru
heterolog
viru
conserv
haemagglutinin
stem
epitop
vrc
initi
novemb
assess
potenti
dna
prime
miv
boost
studi
fulli
enrol
novemb
preliminari
data
indic
need
enrol
two
group
confi
rm
fi
nding
vrc
initi
march
includ
two
group
design
valid
fi
nding
vrc
vrc
vrc
design
examin
safeti
toler
immunogen
investig
infl
uenza
dna
vaccin
encod
dna
boost
miv
subvirion
vaccin
healthi
adult
age
year
histori
infl
uenza
vaccin
bodymass
index
lower
normal
baselin
blood
count
normal
liver
renal
function
laboratori
measur
studi
review
approv
niaid
institut
review
board
individu
provid
written
inform
consent
complet
studi
specifi
c
assess
understand
enrol
follow
human
experiment
guidelin
conduct
clinic
research
us
depart
health
human
servic
enrol
studi
particip
randomli
assign
per
protocol
design
fi
gure
computergener
block
randomis
studi
statistician
pharmacist
develop
maintain
randomis
code
procedur
individu
enrol
vrc
one
four
group
fi
rst
group
serv
control
base
publish
data
assess
miv
vaccin
three
group
serv
experiment
group
design
determin
valu
dna
prime
miv
boost
assess
potenti
eff
ect
boost
interv
number
dose
dna
respons
group
receiv
miv
day
week
group
receiv
dna
day
follow
miv
week
group
receiv
dna
day
follow
miv
week
group
receiv
two
dose
dna
one
day
week
follow
miv
week
partli
design
followup
studi
two
group
vrc
enrol
specifi
calli
valid
fi
nding
vrc
data
two
group
present
vrc
group
receiv
miv
day
week
control
group
includ
vrc
group
b
receiv
dna
day
follow
miv
boost
week
ident
group
vrc
dna
vaccin
mg
given
via
needlefre
biojector
devic
bioject
tualatin
usa
miv
vaccin
administ
needl
syring
dosag
dna
vaccin
miv
vaccin
base
previou
trial
inject
given
intramuscularli
deltoid
assess
local
system
reactogen
day
everi
vaccin
record
advers
event
everi
individu
day
fi
nal
vaccin
primari
safeti
immunogen
endpoint
code
advers
event
use
medic
dictionari
regulatori
activ
sever
scale
assess
neutralis
antibodi
measur
abil
serum
sampl
prevent
infect
cell
replicationincompet
haemagglutininpseudotyp
viru
pseudotyp
viru
express
antigen
luciferas
report
gene
neutralis
activ
quantifi
ed
rel
decreas
luciferas
activ
compar
infect
cell
absenc
sera
base
previous
describ
method
calcul
inhibit
serum
titr
id
rel
signal
absenc
sera
use
fi
veparamet
curv
fi
tting
assess
vaccineinduc
antibodi
haemagglutinin
stem
previous
describ
webappendix
pp
hai
assay
done
vbottom
plate
use
four
haemagglutin
unit
viru
hors
red
blood
cell
previous
describ
viru
strain
use
hai
assay
lowpathogen
reassort
obtain
ruben
doni
center
diseas
control
prevent
infl
uenza
branch
atlanta
ga
usa
clade
assess
elisa
bind
antibodi
direct
antigen
immun
technolog
corpor
new
york
usa
use
dynex
technolog
chantilli
va
usa
plate
coat
prepar
purifi
ed
recombin
protein
accord
method
adapt
previous
describ
endpoint
titr
calcul
dilut
serum
concentr
gave
optic
densiti
read
background
cell
respons
assess
week
miv
boost
everi
individu
intracellular
cytokin
stain
interleukin
interferon
previous
describ
dna
vaccin
manufactur
vrcniaidvaccin
pilot
plant
oper
saic
frederick
md
consist
singl
closedcircular
plasmid
dna
macromolecul
express
infl
uenza
haemagglutinin
sequenc
deriv
human
isol
infl
uenza
sequenc
databas
number
lo
alamo
nation
laboratori
databas
plasmid
contain
cmvr
promot
previous
describ
plasmid
dna
prepar
good
manufactur
practic
mgml
phosphat
buff
ere
salin
pb
primari
outcom
studi
relat
safeti
secondari
outcom
relat
antibodi
respons
exploratori
outcom
relat
tcell
respons
report
posit
respons
rate
exact
ci
everi
antibodi
tcell
respons
report
respons
magnitud
posit
respond
geometr
mean
ci
assess
antibodi
respons
haemagglutinin
elisa
hai
neutralis
assay
compar
studi
group
fisher
exact
test
respons
rate
wilcoxon
test
respons
magnitud
comput
exact
ci
base
exact
binomi
distribut
pearsonclopp
method
statist
softwar
r
version
vrc
vrc
regist
clinicaltri
gov
number
respect
studi
fund
intramur
nation
institut
allergi
infecti
diseas
niaid
niaid
sponsor
trial
trial
conduct
vaccin
research
center
niaid
correspond
author
serv
princip
investig
respons
conduct
studi
accumul
analysi
data
fi
nal
respons
submit
public
healthi
individu
enrol
clinic
trial
vrc
nov
nov
fi
gure
directli
compar
vaccin
regimen
boost
interv
followup
clinic
trial
vrc
initi
individu
enrol
march
may
group
b
enrol
vrc
expand
fi
nding
vrc
fi
gure
demograph
characterist
similar
group
webappendix
p
vaccin
well
toler
vaccinerel
seriou
advers
event
record
present
reactogen
mild
moder
sever
webappendix
pp
antigenspecifi
c
tcell
respons
assess
intracellular
cytokin
stain
week
miv
boost
group
interleukin
interferon
tcell
respons
detect
intracellular
cytokin
stain
frequent
individu
receiv
two
dose
dna
receiv
dna
prime
p
respons
frequent
observ
cell
respons
detect
two
individu
studi
webappendix
p
antibodi
respons
assess
week
miv
boost
individu
neg
antibodi
hai
baselin
tabl
miv
boost
frequenc
posit
indo
hai
respons
greatest
boost
interv
longer
group
b
tabl
hai
titr
geometr
mean
titr
gmt
highest
individu
receiv
dna
prime
boost
longest
interv
group
b
fi
gure
bind
antibodi
assess
elisa
present
individu
boost
magnitud
gmt
elisa
respons
tabl
highest
dna
prime
individu
boost
longer
interv
group
b
fi
gure
e
tabl
neutralis
antibodi
detect
individu
greatest
magnitud
respons
also
seen
group
group
b
fi
gure
f
tabl
assess
whether
stemdirect
neutralis
antibodi
elicit
analys
individu
presenc
antistem
antibodi
immunis
previous
describ
sera
fi
rst
absorb
cell
express
stem
mutant
indo
haemagglutinin
remov
nonstem
direct
antibodi
test
bind
affi
niti
wildtyp
indo
haemagglutinin
figur
show
vaccineinduc
antistem
antibodi
three
repres
individu
one
individu
group
illustr
fi
nding
fi
vetim
increas
bind
immunis
fi
gure
confi
rmed
specifi
citi
antisera
use
competit
elisa
assay
haemagglutinin
bind
done
presenc
antihead
antistem
antibodi
assay
bind
haemagglutinin
inhibit
antistem
antibodi
control
antihead
antibodi
fi
gure
assess
abil
sera
individu
neutralis
heterolog
strain
viru
unmatch
distant
low
pathogenicitiy
amallardpennsylvania
penn
diff
erent
subtyp
ahong
hk
three
repres
individu
fi
gure
postimmun
preimmun
sera
neutralis
unrel
penn
viru
two
individu
also
neutralis
altern
subtyp
hk
viru
fi
gure
document
increas
breadth
immun
sera
furthermor
wildtyp
indo
haemagglutinin
trimer
protein
block
neutralis
strain
fi
gure
c
lower
panel
wildtyp
vs
show
antistem
neutralis
antibodi
induc
vaccin
individu
webappendix
pp
compar
regimen
combin
data
group
vrc
vrc
boost
interv
hai
titr
diff
er
receiv
two
dose
miv
regardless
interv
fi
gure
dna
prime
boost
interv
induc
fourtoninefold
increas
hai
titr
vrc
data
dna
prime
interv
fi
gure
tabl
second
dna
prime
signifi
cantli
increas
magnitud
hai
titr
miv
boost
week
fi
gure
report
analys
abil
dna
vaccin
prime
neutralis
antibodi
respons
elicit
miv
indo
boost
regimen
safe
well
toler
ad
grow
bodi
data
dna
vaccin
carri
favour
safeti
profi
le
safeti
data
assess
dna
vaccin
consist
previou
data
gener
vaccin
research
centr
use
platform
assess
vaccin
hiv
ebola
marburg
west
nile
viru
sever
acut
respiratori
syndrom
viru
season
infl
uenza
individu
immunis
total
dose
dna
vaccin
shown
length
interv
prime
boost
signifi
cantli
aff
ect
magnitud
breadth
respons
dna
prime
increas
potenc
respons
individu
dna
prime
also
increas
breadth
elicit
antibodi
direct
highli
conserv
structur
haemagglutinin
stem
dna
prime
follow
miv
boost
interv
induc
hai
titr
four
time
higher
two
dose
miv
similar
antigen
antigen
gener
induc
lowtitr
lowfrequ
hai
respons
compar
season
infl
uenza
strain
vaccin
antigen
dna
vaccin
assess
studi
previous
shown
induc
hai
titr
individu
given
three
time
mg
dose
without
inactiv
vaccin
boost
similarli
given
twice
miv
boost
product
assess
studi
recent
shown
anoth
group
induc
hai
gmt
although
boost
interv
improv
respons
slightli
gmt
littl
crossreact
antibodi
induc
data
two
clinic
studi
report
singl
dna
prime
boost
miv
week
protect
hai
titr
induc
individu
gmt
group
b
frequenc
magnitud
much
greater
previous
induc
either
vaccin
alon
miv
given
twice
induc
protect
hai
titr
six
individu
group
four
nine
group
fi
nding
remark
rel
weak
immunogen
antigen
one
dose
dna
prime
need
greatli
improv
antibodi
respons
moreov
longer
boost
interv
signifi
cantli
improv
respons
seen
dna
prime
group
signifi
cantli
improv
respons
individu
receiv
two
dose
miv
result
indic
biolog
prime
immunis
diff
er
dna
tradit
inactiv
vaccin
anoth
surpris
fi
nding
two
dose
dna
prime
greatli
improv
overal
respons
beyond
seen
singledos
dna
twodos
dna
prime
aff
ect
elisa
neutralis
antibodi
respons
signifi
cant
eff
ect
hai
respons
known
correl
protect
genebas
antigen
deliveri
access
diff
erent
pathway
antigen
present
might
therebi
facilit
tcell
help
increas
number
divers
clone
induc
greater
expans
relev
bcell
popul
dna
primeinactiv
vaccin
boost
shown
elicit
higher
haemagglutininspecifi
c
tcell
respons
compar
inactiv
vaccin
alon
anim
support
fi
nding
studi
dna
prime
shown
induc
improv
haemagglutinin
immun
respons
anim
studi
research
anim
also
suggest
genebas
infl
uenza
vaccin
induc
broad
protect
across
strain
although
infl
uenzaspecifi
c
broadli
neutralis
antibodi
occasion
detect
man
measur
specifi
c
infl
uenza
vaccineelicit
respons
diffi
cult
sinc
high
preval
variabl
preexist
infl
uenza
immun
gener
popul
benefi
assess
antigen
low
seropreval
despit
share
crossreact
epitop
group
infl
uenza
type
virus
assess
antibodi
induc
genebas
regimen
describ
indic
antibodi
conserv
haemagglutinin
stem
epitop
induc
dna
primemiv
boost
immunis
antibodi
abl
neutralis
divers
strain
includ
induct
stemspecifi
c
neutralis
antibodi
correl
overal
higher
magnitud
antibodi
respons
elicit
genebas
prime
data
previou
studi
suggest
genebas
prime
stimul
increas
helper
tcell
respons
perhap
present
absenc
viral
compon
immun
stimul
could
augment
potenc
breadth
haemagglutinindirect
antibodi
respons
acknowledg
follow
limit
studi
data
deriv
two
sequenti
clinic
trial
rather
one
trial
variabl
stemantibodi
respons
man
remain
poorli
understood
mechan
dna
prime
boost
interv
respons
improv
miv
vaccin
immunogen
remain
unknown
howev
increas
magnitud
antibodi
respons
either
hai
titr
search
pubm
infect
dna
infl
uenza
vaccin
vaccin
antistem
antibodi
univers
infl
uenza
vaccin
relev
articl
referenc
context
throughout
articl
numer
dna
vaccin
report
safe
immunogen
vaccin
gener
less
immunogen
season
infl
uenza
vaccin
dna
prime
previous
shown
induc
signifi
cant
improv
hai
respons
infl
uenza
vaccin
man
determin
data
present
assess
dna
vaccin
prime
miv
boost
healthi
volunt
two
clinic
trial
fi
rst
clinic
trial
reveal
surpris
hai
respons
miv
one
dna
prime
earlier
second
trial
allow
enrol
import
control
group
mivmiv
regimen
interv
confi
rmed
dna
prime
group
higher
hai
titr
miv
week
compar
directli
mivmiv
week
interv
activ
neutralis
antibodi
induc
infl
uenza
vaccin
translat
improv
effi
caci
present
fi
nding
suggest
dna
prime
could
substanti
augment
respons
otherwis
seen
tradit
miv
vaccin
approach
genebas
regimen
may
also
provid
opportun
induc
broader
potenti
potent
neutralis
antibodi
especi
respons
induc
conserv
infl
uenza
epitop
stem
haemagglutinin
longer
boost
interv
might
provid
optimum
immun
respons
allow
fl
exibl
immunis
schedul
moreov
dna
prime
might
also
prove
success
strategi
eff
ort
improv
otherwis
margin
immun
respons
infl
uenza
vaccin
seen
young
elderli
